NEW YORK, NY / ACCESSWIRE / December 31, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
NERV Shareholders Click Here: https://www.zlk.com/pslra-1/minerva-neurosciences-inc-loss-submission-form?prid=11885&wire=1
QIWI Shareholders Click Here: https://www.zlk.com/pslra-1/qiwi-plc-information-request-form?prid=11885&wire=1
TRIT Shareholders Click Here: https://www.zlk.com/pslra-1/triterras-inc-f-k-a-netfin-acquisition-corp-loss-submission-form?prid=11885&wire=1
* ADDITIONAL INFORMATION BELOW *
Minerva Neurosciences, Inc. (NASDAQ:NERV)
NERV Lawsuit on behalf of: investors who purchased May 15, 2017 - November 30, 2020
Lead Plaintiff Deadline : February 8, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/minerva-neurosciences-inc-loss-submission-form?prid=11885&wire=1
According to the filed complaint, during the class period, Minerva Neurosciences, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the truth about the feedback received from the FDA concerning the “end-of-Phase 2” meeting; (ii) the Phase 2b study did not use the commercial formulation of roluperidone and was conducted solely outside of the United States; (iii) the failure of the Phase 3 study to meet its primary and key secondary endpoints rendered that study incapable of supporting substantial evidence of effectiveness; (iv) the Company’s plan to use the combination of the Phase 2b and Phase 3 studies would be “highly unlikely” to support the submission of an NDA; (v) reliance on these two trials in the submission of an NDA would lead to “substantial review issues” because the trials were inadequate and not well-controlled; and (vi) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Qiwi plc (NASDAQ: QIWI)
QIWI Lawsuit on behalf of: investors who purchased March 28, 2019 - December 9, 2020
Lead Plaintiff Deadline : February 9, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/qiwi-plc-information-request-form?prid=11885&wire=1
According to the filed complaint, during the class period, Qiwi plc made materially false and/or misleading statements and/or failed to disclose that: (1) Qiwi’s internal controls related to reporting and record-keeping were ineffective; (2) consequently, the Central Bank of Russia would impose a monetary fine upon the Company and impose restrictions upon the Company’s ability to make payments to foreign merchants and transfer money to pre-paid cards; and (3) as a result, Defendants’ public statements were materially false and/or misleading at all relevant times.
Triterras, Inc., f/k/a Netfin Acquisition Corp. (NASDAQ:TRIT)
TRIT Lawsuit on behalf of: investors who purchased August 20, 2020 - December 16, 2020
Lead Plaintiff Deadline : February 19, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/triterras-inc-f-k-a-netfin-acquisition-corp-loss-submission-form?prid=11885&wire=1
According to the filed complaint, during the class period, Triterras, Inc., f/k/a Netfin Acquisition Corp. made materially false and/or misleading statements and/or failed to disclose that: (1) the extent to which Company’s revenue growth relied on Triterras’ relationship with Rhodium to refer users to the Kratos platform; (2) that Rhodium faced significant financial liabilities that jeopardized its ability to continue as a going concern; (3) that, as a result, Rhodium was likely to refer fewer users to the Company’s Kratos platform; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP